Markets:

Overview

News

Currencies

International

Treasuries

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

446.05 -84.30 (-15.90%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

MEDP Q4 Deep Dive: Cancellations and Metabolic Trial Mix Pressure Margins Despite Strong Growth

February 10, 2026

Clinical research company Medpace Holdings (NASDAQ:MEDP) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 32% year on year to $708.5 million. The company expects the...

Via StockStory

Topics Artificial Intelligence

Medpace (MEDP) Q4 2025 Earnings Call Transcript ↗

February 10, 2026

Medpace (MEDP) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Artificial Intelligence Earnings

Medpace Holdings Inc (NASDAQ:MEDP) Stock Falls Despite Strong Q4 Earnings Beat ↗

February 09, 2026

Via Chartmill

Medpace (NASDAQ:MEDP) Reports Bullish Q4 CY2025

February 09, 2026

Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 32% year on year to $708.5 million. The company expects...

Via StockStory

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results

February 09, 2026

From Medpace Holdings, Inc.

Via Business Wire

Earnings To Watch: Medpace (MEDP) Reports Q4 Results Tomorrow

February 07, 2026

Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results this Monday afternoon. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

3 Market-Beating Stocks to Consider Right Now

February 05, 2026

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends...

Via StockStory

1 Volatile Stock with Solid Fundamentals and 2 We Avoid

January 28, 2026

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced...

Via StockStory

Topics Economy Supply Chain

2 Cash-Heavy Stocks with Promising Prospects and 1 We Find Risky

January 18, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

Via StockStory

Medpace (MEDP): Buy, Sell, or Hold Post Q3 Earnings?

January 15, 2026

What a time it’s been for Medpace. In the past six months alone, the company’s stock price has increased by a massive 96.1%, reaching $617.27 per share. This was partly due to its solid quarterly...

Via StockStory

Topics Supply Chain

2 Healthcare Stocks to Keep an Eye On and 1 We Ignore

January 12, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only...

Via StockStory

Topics Stocks

Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026

January 05, 2026

From Medpace Holdings, Inc.

Via Business Wire

1 Mid-Cap Stock with Competitive Advantages and 2 We Avoid

January 04, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

December 31, 2025

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

2 Profitable Stocks to Keep an Eye On and 1 We Find Risky

December 11, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

1 Volatile Stock to Target This Week and 2 We Turn Down

December 07, 2025

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor...

Via StockStory

Q3 Rundown: Azenta (NASDAQ:AZTA) Vs Other Drug Development Inputs & Services Stocks

November 27, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers.

Via StockStory

Medpace (MEDP) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Medpace (MEDP) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Medpace (NASDAQ:MEDP): Strongest Q3 Results from the Drug Development Inputs & Services Group

November 24, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Medpace (NASDAQ:MEDP) and its peers.

Via StockStory

BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know

November 24, 2025

A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government...

Via StockStory

Topics Economy Government

MEDPACE HOLDINGS INC (NASDAQ:MEDP) Shows Strong Growth and Momentum Alignment ↗

November 21, 2025

MEDP stock shows strong technical momentum and accelerating earnings growth, fitting a proven strategy for finding leading growth stocks.

Via Chartmill

6 Healthcare Stocks With Strong Upward Momentum ↗

November 18, 2025

Via Benzinga

2 Mooning Stocks to Research Further and 1 We Question

November 11, 2025

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Via StockStory

Topics Economy

Drug Development Inputs & Services Stocks Q3 Results: Benchmarking UFP Technologies (NASDAQ:UFPT)

November 11, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including UFP Technologies (NASDAQ:UFPT) and its peers.

Via StockStory

Q3 Earnings Highs And Lows: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

November 06, 2025

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its...

Via StockStory

Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN)

November 06, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers.

Via StockStory

1 Mid-Cap Stock to Target This Week and 2 We Ignore

November 02, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

Via StockStory

3 Cash-Heavy Stocks Worth Your Attention

October 30, 2025

In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for their financial discipline, resilience, and...

Via StockStory

5 Revealing Analyst Questions From Medpace’s Q3 Earnings Call

October 29, 2025

Medpace’s third quarter results were well received by the market, driven by broad-based revenue growth and robust net new business awards. Management credited strong demand across therapeutic...

Via StockStory

Topics Earnings

8 Analysts Assess Medpace Hldgs: What You Need To Know ↗

October 24, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.